当前位置:首页>产品中心>单抗/多抗>Anti-Human KCNA5 Polyclonal Antibody|抗人KCNA5多克隆抗体(靶标:人电压门控钾通道亚家族A成员5/Kv1.5)

Anti-Human KCNA5 Polyclonal Antibody|抗人KCNA5多克隆抗体(靶标:人电压门控钾通道亚家族A成员5/Kv1.5)

  • 货号:RB9THB985014
  • 价格:面议
  • 点击:644
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human, Rat, Mouse
靶标HPCN1, KCNA5, Potassium voltage-gated channel subfamily A member 5, Voltage-gated potassium channel HK2, Voltage-gated potassium channel subunit Kv1.5
免疫原E. coli - derived recombinant Human KCNA5 (Thr106-Gly247).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号P22460
背景信息

Potassium voltage-gated channel subfamily A member 5 (KCNA5) is a ~67 kDa protein. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation.

1. Williams, CP. et al. (2002) The Journal of pharmacology and experimental therapeutics 302, 545-50. PMID: 12130714
2. Snyders, DJ. et al. (1993) The Journal of general physiology 101, 513-43. PMID: 8505626
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 871
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 902
Anti-Sarilumab Neutralizing Recombinant Antibody |抗萨瑞鲁单抗中和重组抗体(靶标:萨瑞鲁单抗中和抗体) 844
Anti-Durvalumab Non-Neutralizing Recombinant Antibody |程度伐利尤单抗非中和重组抗体(靶标:度伐利尤单抗非中和抗体) 1164
Anti-Durvalumab Non-Neutralizing Recombinant Antibody |抗度伐利尤单抗非中和重组抗体(靶标:度伐利尤单抗非中和抗体) 1110
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 907
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 1023
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 891
Anti-Durvalumab Neutralizing Recombinant Antibody |抗度伐利尤单抗中和重组抗体(靶标:度伐利尤单抗中和抗体) 932
Anti-Atezolizumab Non-Neutralizing Recombinant Antibody |抗阿替利珠单抗非中和重组抗体(靶标:阿替利珠单抗非中和抗体) 901
Anti-Atezolizumab Non-Neutralizing Recombinant Antibody |抗阿替利珠单抗非中和重组抗体(靶标:阿替利珠单抗非中和抗体) 901
Anti-Atezolizumab Neutralizing Recombinant Antibody |抗阿替利珠单抗中和重组抗体(靶标:阿替利珠单抗中和抗体) 852
Anti-Atezolizumab Neutralizing Recombinant Antibody |抗阿替利珠单抗中和重组抗体(靶标:阿替利珠单抗中和抗体) 1007
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 1128
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 857
Anti-Panitumumab Non-Neutralizing Recombinant Antibody |抗帕尼单抗非中和重组抗体(靶标:帕尼单抗非中和抗体) 858
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 854
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 831
Anti-Panitumumab Neutralizing Recombinant Antibody |抗帕尼单抗中和重组抗体(靶标:帕尼单抗中和抗体) 781
Anti-Ixekizumab Non-Neutralizing Recombinant Antibody |抗依奇珠单抗非中和重组抗体(靶标:依奇珠单抗非中和抗体) 835
总计 33036 个记录,共 1652 页,当前第 1647 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30